Resilience to resistance of HIV-1 protease inhibitors: Profile of darunavir

AIDS Reviews

Volumn 10, Issue 3, 2008, Pages 131-142

  Lefebvre, Eric ^a   Schiffer, Celia A ^b  

^a Janssen Cilag BV Netherlands   (Netherlands)

^b UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

Author keywords

Darunavir; Drug resistance; HIV; HIV 1 protease; Substrate recognition; TMC114

Indexed keywords

AMPRENAVIR; ANTIRETROVIRUS AGENT; CD4 ANTIGEN; DARUNAVIR; ENFUVIRTIDE; INDINAVIR; LOPINAVIR; LOPINAVIR PLUS RITONAVIR; NELFINAVIR; PROTEINASE; PROTEINASE INHIBITOR; RITONAVIR; SAQUINAVIR; TIPRANAVIR; TMC 126; UNCLASSIFIED DRUG; VIRUS ENVELOPE PROTEIN;

ANTIVIRAL RESISTANCE; ANTIVIRAL SUSCEPTIBILITY; BINDING AFFINITY; CD4+ T LYMPHOCYTE; CLINICAL TRIAL; COUGHING; CROSS RESISTANCE; DIARRHEA; DRUG APPROVAL; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG POTENCY; DRUG PROTEIN BINDING; DRUG RESEARCH; DRUG SAFETY; DRUG STRUCTURE; DRUG TARGETING; DRUG TOLERABILITY; DRUG WITHDRAWAL; ENZYME ACTIVE SITE; ENZYME STRUCTURE; ENZYME SUBSTRATE; FATIGUE; FEVER; FOOD AND DRUG ADMINISTRATION; HEADACHE; HERPES SIMPLEX; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HYDROGEN BOND; IN VITRO STUDY; INSOMNIA; LOW DRUG DOSE; LYMPHOCYTE COUNT; MEDICAL DECISION MAKING; MULTIDRUG RESISTANCE; NAUSEA; RECOMMENDED DRUG DOSE; REVIEW; RHINOPHARYNGITIS; THERMODYNAMICS; UPPER RESPIRATORY TRACT INFECTION; VIRUS INHIBITION; VIRUS LOAD; VIRUS REPLICATION; VIRUS STRAIN; VIRUS VIRULENCE; WILD TYPE;

CLINICAL TRIALS AS TOPIC; DRUG RESISTANCE, VIRAL; HIV INFECTIONS; HIV PROTEASE; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; MODELS, MOLECULAR; RITONAVIR; STRUCTURE-ACTIVITY RELATIONSHIP; SUBSTRATE SPECIFICITY; SULFONAMIDES; TREATMENT OUTCOME;

EID: 55049134097     PISSN: 11396121     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (83)

1. Harrigan P, Larder B. Extent of cross-resistance between agents used to treat HIV-1 infection in clinically derived isolates. Antimicrob Agents Chemother. 2002;46:909-12.
2. Leigh-Brown A, Frost S, Mathews W, et al. Transmission fitness of drug-resistant HIV and the prevalence of resistance in the antiretroviral-treated population. J Infect Dis. 2003;187:683-6.
3. Richman D, Morton S, Wrin T, et al. The prevalence of antiretroviral drug resistance in the United States. AIDS. 2004;18:1393-401.
4. Yerly S, Jost S, Telenti A, et al. Infrequent transmission of HIV-1 drug-resistant variants. Antivir Ther. 2004;9:375-84.
5. Miller V. International perspectives on antiretroviral resistance. Resistance to protease inhibitors. J Acquir Immune Defic Syndr. 2001;26(Suppl 1): S34-50.
6. Grant R, Hecht F, Warmerdam M, et al. Time trends in primary HIV-1 drug resistance among recently infected persons. JAMA. 2002; 288:181-8.
7. Grossman Z, Lorber M. Maayan S, et al. Drug-resistant HIV infection among drug-naive patients in Israel. Clin Infect Dis. 2005;40:294-302.
8. Little S, Holte S, Routy J, et al. Antiretroviral-drug resistance among patients recently infected with HIV. N Engl J Med. 2002;347:385-94.
9. Wensing A, Van de Vijver D, Asjo B. et al. Analysis from more than 1600 newly diagnosed patients with HIV from 17 European countries shows that 10% of the patients carry primary drug resistance: the CATCH-Study. 2nd IAS Conference on HIV Pathogenesis and Treatment. Paris, France. 2003 [abstract LB01].
10. Greub G, Cozzi-Lepri A, Ledergerber B, et al. Intermittent and sustained low-level HIV viral rebound in patients receiving potent antiretroviral therapy. AIDS. 2002;16:1967-9.
11. Karlsson A, Younger S, Martin J, et al. Immunologic and virologic evolution during periods of intermittent and persistent low-level viremia. AIDS. 2004;18:981-9.
12. Sklar P, Ward D, Baker R, et al. Prevalence and clinical correlates of HIV viremia ('blips') in patients with previous suppression below the limits of quantification. AIDS. 2002;16:2035-41.
13. Kohl N, Emini E, Schleif W, et al. Active HIV protease is required for viral infectivity. Proc Natl Acad Sci USA. 1988;85:4686-90.
14. Tomasselli A, Heinrikson R. Targeting the HIV-protease in AIDS therapy: a current clinical perspective. Biochim Biophys Acta. 2000;1477: 189-214.
15. King N, Prabu-Jeyabalan M, Nalivaika E, Wigerinck P, de Béthune M, Schiffer C. Structural and thermodynamic basis for the binding of TMC114, a next-generation HIV-1 protease inhibitor. J Virol. 2004;78: 12012-21.
16. Surleraux D, Tahri A, Verschueren W, et al. Discovery and selection of TMC 114, a next generation HIV-1 protease inhibitor. J Med Chem. 2005;48:1813-22.
17. Surleraux D, de Kock H, Verschueren W, et al. Design of HIV-1 protease inhibitors active on multidrug-resistant virus. J Med Chem. 2005;48: 1965-73.
18. Pettit S, Michael S, Swanstrom R. The specificity of the HIV-1 protease. Perspect Drug Discov Design. 1993;1:69-83.
19. Peng C, Ho B, Chang T, Chang N. Role of HIV-1-specific protease in core protein maturation and viral infectivity. J Virol. 1989;63:2550-6.
20. Turner B, Summers M. Structural biology of HIV. J Mol Biol. 1999;285:1-32.
21. Wlodawer A, Gustchina A. Structural and biochemical studies of retroviral proteases. Biochim Biophys Acta. 2000;1477:16-34.
22. Wlodawer A, Erickson J. Structure-based inhibitors of HIV-1 protease. Annu Rev Biochem. 1993;62:543-85.
23. Rose R, Craik C, Stroud R. Domain flexibility in retroviral proteases: structural implications for drug-resistant mutations. Biochemistry. 1998; 37:2607-21.
24. Scott W, Schiffer C. Curling of flap tips in HIV-1 protease as a mechanism for substrate entry and tolerance of drug resistance. Structure. 2000;8:1259-65.
25. Perryman A, Lin J, McCammon J. HIV-1 protease molecular dynamics of a wild-type and of the V82F/I84V mutant: possible contributions to drug resistance and a potential new target site for drugs. Protein Sci. 2004;13:1108-23.
26. Liu F, Boross P, Wang Y. et al. Kinetic, stability, and structural changes in high-resolution crystal structures of HIV-1 protease with drug-resistant mutations L241, I50V, and G73S. J Mol Biol. 2005; 354:789-800.
27. Tie Y, Boross P, Wang Y, et al. Molecular basis for substrate recognition and drug resistance from 1.1 to 1.6 angstroms resolution crystal structures of HIV-1 protease mutants with substrate analogs. FEBS J. 2005; 272:5265-77.
28. Mahalingam B, Louis J, Hung J, Harrison R, Weber I. Structural implications of drug-resistant mutants of HIV-1 protease: high-resolution crystal structures of the mutant protease/substrate analog complexes. Proteins. 2001;43:455-64.
29. Mahalingam B, Boross P, Wang Y, et al. Combining mutations in HIV-1 protease to understand mechanisms of resistance. Proteins. 2002;48:107-16.
30. Prabu-Jeyabalan M, Nalivaika E, Schiffer C. How does a symmetric dimer recognize an asymmetric substrate? A substrate complex of HIV-1 protease. J Mol Biol. 2000;301:1207-20.
31. Prabu-Jeyabalan M, Nalivaika E, Schiffer C. Substrate shape determines specificity of recognition for HIV-1 protease: analysis of crystal structures of 6 substrate complexes. Structure. 2002;10:369-81.
32. Prabu-Jeyabalan M, Nalivaika E, King N, Schiffer C. Viability of a drug-resistant HIV-1 protease variant: structural insights for better antiviral therapy. J Virol. 2003;77:1306-15.
33. Prabu-Jeyabalan M, Nalivaika E, King N, Schiffer C. Structural basis for co-evolution of a HIV-1 nucleocapsid-p1 cleavage site with a V82A drug-resistant mutation in viral protease. J Virol. 2004;78:12446-54.
34. King N, Prabu-Jeyabalan M, Nalivaika E, Schiffer C. Combating susceptibility to drug resistance: lessons from HIV-1 protease. Chem Biol. 2004;11:1333-8.
35. Kim E, Baker C, Dwyer M, et al. Crystal structure of HIV-1 protease in complex with VX-478, a potent and orally bioavailable inhibitor of the enzyme. J Am Chem Soc. 1995;117:1181-2.
36. Chen Z, Li Y, Chen E, et al. Crystal structure at 1.9-A resolution of HIV II protease complexed with L-735,524, an orally bioavailable inhibitor of the HIV proteases. J Biol Chem. 1994;269:26344-8.
37. Krohn A, Redshaw S, Ritchie J, Graves B, Hatada M. Novel binding mode of highly potent HIV-proteinase inhibitors incorporating the (R)- hydroxyethylamine isostere. J Med Chem. 1991;34:3340-2.
38. Kempf D, Marsh K, Denissen J, et al. ABT-538 is a potent inhibitor of HIV protease and has high oral bioavailability in humans. Proc Natl Acad Sci USA. 1995;92:2484-8.
39. Kaldor S, Kalish V, Davies J, et al. Viracept (nelfinavir mesylate, AG1343): a potent, orally bioavailable inhibitor of HIV-1 protease. J Med Chem. 1997;40:3979-85.
40. Stoll V, Qin W, Stewart K, et al. X-ray crystallographic structure of ABT-378 (lopinavir) bound to HIV-1 protease. Bioorg Med Chem. 2002;10:2803-6.
41. Thaisrivongs S, Strohbach J. Structure-based discovery of tipranavir disodium (PNU-140690E): a potent, orally bioavailable, nonpeptidic HIV protease inhibitor. Biopolymers. 1999;51:51-8.
42. Yanchunas J Jr, Langley D, Tao L, et al. Molecular basis for increased susceptibility of isolates with atazanavir resistance-conferring substitution 150L to other protease inhibitors. Antimicrob Agents Chemother. 2005;49:3825-32.
43. Todd M, Luque I, Velazquez-Campoy A, Freire E. Thermodynamic basis of resistance to HIV-1 protease inhibition: calorimetric analysis of the V82F/I84V active site resistant mutant. Biochemistry. 2000;39:11876-83.
44. Velazquez-Campoy A, Luque I, Todd M, Milutinovich M, Kiso Y, Freire E. Thermodynamic dissection of the binding energetics of KNI-272, a potent HIV-1 protease inhibitor. Protein Sci. 2000;9:1801-9.
45. Ohtaka H, Muzammil S, Schon A, Velazquez-Campoy A, Vega S, Freire E. Thermodynamic rules for the design of high affinity HIV-1 protease inhibitors with adaptability to mutations and high selectivity towards unwanted targets. Int J Biochem Cell Biol. 2004;36:1787-99.
46. Ohtaka H, Freire E. Adaptive inhibitors of the HIV-1 protease. Prog Biophys Mol Bol. 2005;88:193-208.
47. King N, Melnick L. Prabu-Jeyabalan M, et al. Lack of synergy for inhibitors targeting a multidrug-resistant HIV-1 protease. Protein Sci. 2002;11:418-29.
48. Koh Y, Nakata H, Maeda K, et al. Novel bis-tetrahydrofuranylurethane-containing nonpeptidic protease inhibitor UIC-94017 (TMC114) with potent activity against multi-PI-resistant HIV in vitro. Antimicrob Agents Chemother. 2003;47:3123-9.
49. Tie Y, Boross P, Wang Y, et al. High resolution crystal structures of HIV-1 protease with a potent non-peptide inhibitor (UIC-94017) active against multidrug-resistant clinical strains. J Mol Biol. 2004; 338:341-52.
50. Kovalevsky A, Tie Y, Liu F, et al. Effectiveness of nonpeptide clinical inhibitor TMC-114 on HIV-1 protease with highly drug resistant mutations D30N, I50V, and L90M. J Med Chem. 2006;49:1379-87.
51. De Meyer S, Azjin H, Surleraux D, et al. TMC114, a novel HIV-1 protease inhibitor active against protease inhibitor-resistant viruses, including a broad range of clinical isolates. Antimicrob Agents Chemother. 2005;49:2314-21.
52. Dierynck I, Keuleers I, De Wit M, et al. Kinetic characterization of the potent activity of TMC114 on wild-type HIV-1 protease. 14th International HIV Drug Resistance Workshop, Québec City, Canada, 2005 [abstract 64].
53. Chong K-T, Pagano PJ. In vitro combination of PNU-140690, a HIV-1 protease inhibitor, with ritonavir against ritonavir-sensitive and -resistant clinical isolates. Antimicrob Agents Chemother. 1997;41:2367-73.
54. Muzammil S, Armstrong AA, Kang LW, et al. Unique thermodynamic response of tipranavir to HIV-1 protease drug resistance mutations. J Virol. 2007;81:5144-54.
55. Clavel F, Hance A. HIV drug resistance. N Engl J Med. 2004;350: 1023-35.
56. Wu T, Schiffer C, Gonzales M, et al. Mutation patterns and structural correlates in HIV-1 protease following different protease inhibitor treatments. J Virol. 2003;77:4836-47.
57. Rhee S, Fessel W, Zolopa A, et al. HIV-1 Protease and reverse transcriptase mutations: correlations with antiretroviral therapy in subtype B isolates and implications for drug-resistance surveillance. J Infect Dis. 2005;192:456-65.
58. Hoffman N, Schiffer C, Swanstrom R. Co-variation of amino acid positions in HIV-1 protease. Virology. 2003;314:536-48.
59. De Mendoza C, Soriano V. Resistance to HIV protease inhibitors: mechanisms and clinical consequences. Curr Drug Metab. 2004;5:321-8.
60. Watkins T, Resch W, Irlbeck D, Swanstrom R. Selection of high level resistance to HIV-1 protease inhibitors. Antimicrob Agents Chernother. 2003;47:759-69.
61. Schock H, Garsky V, Kuo L. Mutational anatomy of an HIV-1 protease variant conferring cross-resistance to protease inhibitors in clinical trials. Compensatory modulations of binding and activity. J Biol Chem. 1996;271:31957-63.
62. Hertogs K, Bloor S, Kemp S, et al. Phenotypic and genotypic analysis of clinical HIV-1 isolates reveals extensive protease inhibitor cross-resistance: a survey of over 6000 samples. AIDS. 2000;14:1203-10.
63. Kemper C, Witt M, Keiser P, et al. Sequencing of protease inhibitor therapy: insights from an analysis of HIV phenotypic resistance in patients failing protease inhibitors. AIDS. 2001;15:609-15.
64. Shafer R, Hsu P, Patick A, Craig C, Brendel V. Identification of biased amino acid substitution patterns in HIV-1 isolates from patients treated with protease inhibitors. J Virol. 1999;73:6197-202.
65. Shafer R, Stevenson D, Chan B. HIV reverse transcriptase and protease sequence database. Nucleic Acids Res. 1999;27:348-52.
66. Mitsuya Y, Liu TF, Rhee SY, et al. Prevalence of darunavir resistance-associated mutations: patterns of occurrence and association with past treatment. J Infect Dis, 2007;196:1177-9.
67. Poveda E, de Mendoza C, Martin-Carbonero L, et al. Prevalence of darunavir resistance mutations in HIV-1-infected patients failing other protease inhibitors. J Antimicrob Chemother. 2007;60:885-8.
68. Picchio G, Vangeneugden T, Van Baelen B, et al. Prior utilization/ resistance to amprenavir at screening has minimal impact on the 48-week response to darunavir/r in the POWER 1, 2 and 3 studies. 14th CROI, Los Angeles, CA, USA, 2007 [abstract 609].
69. Kempf D, Isaacson J, King M, et al. Identification of genotypic changes in HIV protease that correlate with reduced susceptibility to the protease inhibitor lopinavir among viral isolates from protease inhibitor-experienced patients. J Virol. 2001;75:7462-9.
70. Schinazi R, Larder B, Mellors W. Mutations in retroviral genes associated with drug resistance. Int Antiviral News. 1997;5:129-42.
71. Ohtaka H, Velazquez-Campoy A, Xie D, Freire E. Overcoming drug resistance in HIV-1 chemotherapy: the binding thermodynamics of amprenavir and TMC-126 to wild-type and drug-resistant mutants of the HIV-1 protease. Protein Sci. 2002;11:1908-16.
72. Mo H, Lu L, Dekhtyar T, et al. Characterization of resistant HIV variants generated by in vitro passage with lopinavir/ritonavir. Antiviral Res. 2003;59:173-80.
73. Yoshimura K, Kato R, Kavlick M, et al. A potent HIV-1 protease inhibitor, UIC-94003 (TMC-126), and selection of a novel (A28S) mutation in the protease active site. J Virol. 2002;76:1349-58.
74. De Meyer S. Azijn H, Fransen E, et al. The pathway leading to TMC114 resistance is different for TMC114 compared with other protease inhibitors. 15th International HIV Drug Resistance Workshop, Sitges, Spain, 2006 [abstract 19].
75. Arastéh K, Clumeck N, Pozniak A, et al. TMC114/ritonavir substitution for protease inhibitor(s) in a non-suppressive antiretroviral regimen: a 14-day proof-of-principle trial. AIDS. 2005; 19:943-7.
76. Katlama C, Esposito R, Gatell J, et al. Efficacy and safety of TMC114/ ritonavir in treatment-experienced HIV patients: 24-week results of POWER 1. AIDS. 2007;21:395-402.
77. Haubrich R, Berger D, Chiliade P, et al. Week 24 efficacy and safety of TMC114/ritonavir in treatment-experienced HIV patients. AIDS. 2007;21:F11-18.
78. Molina JM, Cohen C, Katlama C, et al. Safety and efficacy of darunavir (TMC114) with low-dose ritonavir in treatment-experienced patients: 24-week results of POWER 3. J Acquir Immune Defic Syndr. 2007;46:24-31.
79. Clotet B, Bellos N, Molina J-M, et al. Efficacy and safety of darunavir-ritonavir at week 48 in treatment-experienced patients with HIV-1 infection in POWER 1 and 2: a pooled subgroup analysis of data from two randomised trials. Lancet. 2007;369:1169-78.
80. Valdez-Madruga J, Berger D, McMurchie M, et al. Efficacy and safety of darunavir-ritonavir compared with that of lopinavir-ritonavir at 48 weeks in treatment-experienced, HIV-infected patients in TITAN: a randomised controlled phase III trial. Lancet. 2007;370:49-58.
81. DeJesus E, Ortiz R, Khanlou H, et al. Efficacy and safety of darunavir/ ritonavir versus lopinavir/ritonavir in ARV treatment-naive patients at week 48: ARTEMIS. 47th ICAAC, Chicago, IL, USA, 2007 [abstract H-718b].
82. Tibotec BVBA, Mechelen, Belgium. Data on file.
83. De Meyer S, Hill A, De Baere I, et al. Effect of baseline susceptibility and on-treatment mutations on TMC114 and control PI efficacy: preliminary analysis of data from PI-experienced patients from POWER 1 and POWER 2. 13th CROI, Denver, CO, USA, 2006 [abstract 157].